Friday, August 21, 2026

Discover JYP’s New Girl Group: OURBIRTHDAY’s Unique WHIP-HOP Sound

JYP's OURBIRTHDAY debuts with vibrant visuals, creating an exciting and free-spirited atmosphere.

North Korea Denies Troop Deployment to Russia Amid Growing Casualty Reports and Internal Rumors

North Korea denies military casualties in Russia, accusing the U.S. of spreading false information while facing internal dissent.

Samsung C&T and ENEC Sign MOU to Expand Global Nuclear Power Cooperation

Samsung C&T partners with ENEC to enhance global nuclear power development, focusing on construction, investment, and innovation.

Tag: Hanmi Pharmaceutical

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Why Hanmi Pharmaceutical’s Pyeongtaek Manufacturing Center Achieved Top Safety Rating Again in 2026?

Hanmi Pharmaceutical's Pyeongtaek manufacturing center received the highest P grade in a safety management assessment by the Ministry of Employment and Labor.

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

A Record Year in China Is Giving Hanmi Pharmaceutical More Firepower for What’s Next

Hanmi Pharmaceutical's Chinese subsidiary surpassed $290M in sales, contributing significantly to the group's growth and future investments.

Hanmi Pharmaceutical’s Leadership Shake-Up: What Does New CEO Hwang Sang-yeon Mean for the Future?

Hanmi Pharmaceutical Group's management dispute appears to be resolved, marking its first external leadership in 53 years.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

FDA Grants Breakthrough Therapy Designation to Hanmi’s Epheglucagon: What This Means for Rare Disease Treatment

Hanmi Pharmaceutical's efpegerglucagon receives FDA Breakthrough Therapy designation for treating rare Congenital Hyperinsulinism, with Phase 2 results due soon.

How MiniRin and Nokdernah Are Revolutionizing Nocturia Care for Seniors: A Comprehensive Guide

Hanmi Pharmaceutical and Ferring Korea partner to distribute Minirin and Nocdurna for nocturia treatment, enhancing patient access.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.